BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT.

The live webcast of this event can be accessed from the investors section of the Company’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 1 year following the event.

About BeiGene

BeiGene, which will change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents. To learn more about BeiGene, please visit www.beigene.com.

Forward-Looking Statements

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250513199895/en/

Investors:

Liza Heapes

+1 857-302-5663

ir@beigene.com

Media:

Kim Bencker

+1 610-256-8932

media@beigene.com

Source: BeiGene, Ltd.